IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...
The experimental precision drug, developed with Japan's Daiichi Sankyo, did not significantly improve overall survival rates ...
It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...
PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...
EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...
Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...
Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
European stock markets rallied on Monday afternoon to finish with moderate gains as dismal economic data increased hopes that ...
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback